Tonix Pharmaceuticals Secures US Patent Claiming Pharmaceutical Composition, Method Of Treating Migraine Via Intranasal Administration, And An Intranasal Delivery System For Tosymra. This Patent, Excluding Possible Patent Term Extensions, Is Expected To Expire In 2030.
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has secured a US patent for a pharmaceutical composition and method for treating migraines via intranasal administration, specifically for their product Tosymra. The patent is set to expire in 2030, excluding any extensions.
September 19, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals has obtained a US patent for Tosymra, a migraine treatment administered intranasally. This patent strengthens their intellectual property portfolio and could enhance their market position until 2030.
The patent secures Tonix's intellectual property for Tosymra, potentially increasing its market value and competitive edge in the migraine treatment sector. This could lead to positive investor sentiment and a short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100